Shire PLC , which in-licenses marketed or close-to-market drugs in specialist areas, has been one of the industry's fastest-growing firms, driven by an aggressive acquisition strategy and strong marketing.
But shareholders are becoming disenchanted. In the first place, the firm's most important product, Adderall, a mixture of four amphetamine...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?